Key Highlights
- Revenue was USD 10.37 million against an estimate of USD 4.46 million.
- Loss per share was USD 0.15 against an estimate of a USD 0.19 loss.
- Net loss was USD 23.4 million, against USD 25.1 million a year earlier.
- Cash and marketable securities were USD 190.2 million at September 30.
Editas Medicine (NASDAQ:EDIT) reported third quarter 2026 Revenue of USD 10.37 million, against an estimate of USD 4.46 million. The loss per share was USD 0.15, compared with an estimate of a USD 0.19 loss and a USD 0.28 loss in the third quarter of 2025.
Net loss was USD 23.39 million, against USD 25.12 million in the prior-year quarter. The operating loss was USD 24.28 million, compared with USD 24.55 million, and the nine-month operating loss was USD 67.84 million, against USD 152.26 million. The figures come from the company's quarterly filing for the period ended September 30, 2026.
Collaboration Revenue and Operating Expenses
Collaboration and other Research and Development revenues increased by USD 2.8 million to USD 10.4 million for the three months ended September 30, 2026, compared with USD 7.5 million in the same period of 2025. The filing describes multiple collaborations, out-licenses and strategic alliances that involve upfront, research service, option, milestone and Royalty payments.
Total operating expenses were USD 34.65 million, against USD 32.09 million a year earlier. Research and development expenses increased by USD 1.4 million to USD 21.2 million, and general and administrative expenses increased by USD 1.2 million to USD 13.5 million.
Nine-Month Results
For the nine months ended September 30, 2026, net loss was USD 66.61 million, compared with USD 154.44 million in the same period of 2025. The loss per share for the nine months was USD 0.54, against USD 1.80.
Operating expenses for the nine months were USD 92.93 million, against USD 168.03 million. Research and development expenses for the period were USD 58.95 million, compared with USD 62.55 million, and general and administrative expenses were USD 35.31 million, against USD 38.55 million.
Cash Position and Collaborations
As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 190.2 million. Cash and cash equivalents were USD 93.17 million, down from USD 146.65 million at the prior Balance Sheet date, and marketable securities were USD 97.03 million.
The filing states that, in addition to its existing cash, cash equivalents and marketable securities, the company is eligible to earn milestone and other payments under its collaboration with BMS and its other collaboration and license agreements. It also notes that interest accretion related to the Liability for the sale of future revenues was lower than in the prior-year quarter.
The filing also discusses a Lease termination. The company entered into a license and service agreement in 2023 for Manufacturing space used in its research and development activities, modified it in September 2024, and agreed in April 2025 to terminate it on April 30, 2025 with a final fixed payment of USD 3.7 million.
Editas Medicine Q3 2026 Earnings: Key Takeaways
Editas Medicine reported third quarter 2026 revenue of USD 10.37 million and a loss per share of USD 0.15. Net loss was USD 23.39 million, and cash, cash equivalents and marketable securities were USD 190.2 million.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...